Search - tctmd.com

Displaying 41 - 60 of 63

Sort: Relevancy | Date

News Conference News ESC 2016

DOCTORS: Optical Coherence Tomography Improves Stent Placement, Ups FFR in NSTE ACS

Shelley Wood

August 30, 2016

News Conference News ESC 2016

Platelet Function Testing to Guide Treatment Does Not Benefit Elderly ACS Patients: ANTARCTIC

Todd Neale

August 28, 2016

News Conference News ESC 2016

NIPPON: With Nobori Stent, 6 Months of DAPT as Safe and Effective as 18 Months

Michael O'Riordan

August 28, 2016

News Conference News ESC 2015

MATRIX Antithrombin: Bivalirudin Fails to Reduce Net Adverse Events vs Heparin in ACS Patients Undergoing PCI

Yael L. Maxwell

September 02, 2015

News Conference News ESC 2015

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

L.A. McKeown

August 31, 2015

News Conference News ESC 2014

RITA-3: Advantage of Routine Invasive Strategy for NSTE-ACS Gone by 10 Years

Caitlin E. Cox

September 03, 2014

Presentation ESC 2014

10-year mortality outcome of a routine invasive strategy in non-ST segment elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial

Presenter: Robert A. Henderson

September 02, 2014

News Conference News ESC 2014

FAMOUS-NSTEMI: FFR Guidance Reduces Revascularization in NSTEMI

Todd Neale

September 01, 2014

News Conference News ESC 2014

SOLID-TIMI 52: Darapladib Fails to Reduce Adverse Events After ACS

Yael L. Maxwell

August 31, 2014

News Conference News ESC 2013

CHAMPION: Cangrelor Bests Clopidogrel in PCI Patients in Large Meta-analysis

Yael L. Maxwell

September 03, 2013

News Conference News ESC 2013

BIC-8: Positive Signs for Early-Rule Out of Suspected ACS Using Copeptin

Caitlin E. Cox

September 03, 2013

News Conference News ESC 2013

TAO: Otamixaban Fails to Outshine Heparin Plus Eptifibatide in NSTE-ACS

Caitlin E. Cox

September 01, 2013

News Conference News ESC 2013

ACCOAST: Prasugrel Pretreatment Increases Bleeding in NSTE-ACS

Yael L. Maxwell

September 01, 2013

Presentation ESC 2012

Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial

Presenter: Matthew Roe

August 28, 2012

News Conference News ESC 2012

Low-Dose Rivaroxaban Curbs Thrombotic Events in STEMI Patients

Caitlin E. Cox

August 27, 2012

News Conference News ESC 2012

Comparable Long-Term Safety, Efficacy with Prasugrel, Clopidogrel in ACS

August 26, 2012

News Conference News

Study Investigates Which Elderly Patients Benefit from Aggressive Treatment

September 01, 2011

News Conference News

Japanese ACS Patients Fare Better with High Rates of Intensive Treatment

September 01, 2011

News Conference News

Halting Clopidogrel in First Year Following Acute MI Hazardous

September 01, 2011

News Conference News

RUBY-1: Yet Another Novel Anticoagulant Tested in ACS Patients on Antiplatelets

August 31, 2011

Advertisement

DOCTORS: Optical Coherence Tomography Improves Stent Placement, Ups FFR in NSTE ACS

Platelet Function Testing to Guide Treatment Does Not Benefit Elderly ACS Patients: ANTARCTIC

NIPPON: With Nobori Stent, 6 Months of DAPT as Safe and Effective as 18 Months

MATRIX Antithrombin: Bivalirudin Fails to Reduce Net Adverse Events vs Heparin in ACS Patients Undergoing PCI

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

RITA-3: Advantage of Routine Invasive Strategy for NSTE-ACS Gone by 10 Years

10-year mortality outcome of a routine invasive strategy in non-ST segment elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial

FAMOUS-NSTEMI: FFR Guidance Reduces Revascularization in NSTEMI

SOLID-TIMI 52: Darapladib Fails to Reduce Adverse Events After ACS

CHAMPION: Cangrelor Bests Clopidogrel in PCI Patients in Large Meta-analysis

BIC-8: Positive Signs for Early-Rule Out of Suspected ACS Using Copeptin

TAO: Otamixaban Fails to Outshine Heparin Plus Eptifibatide in NSTE-ACS

ACCOAST: Prasugrel Pretreatment Increases Bleeding in NSTE-ACS

Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial

Low-Dose Rivaroxaban Curbs Thrombotic Events in STEMI Patients

Comparable Long-Term Safety, Efficacy with Prasugrel, Clopidogrel in ACS

Study Investigates Which Elderly Patients Benefit from Aggressive Treatment

Japanese ACS Patients Fare Better with High Rates of Intensive Treatment

Halting Clopidogrel in First Year Following Acute MI Hazardous

RUBY-1: Yet Another Novel Anticoagulant Tested in ACS Patients on Antiplatelets

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content